Takeda Pharmaceutical Co. Ltd. Takes Position in HilleVax, Inc. (NASDAQ:HLVX)

Takeda Pharmaceutical Co. Ltd. acquired a new position in HilleVax, Inc. (NASDAQ:HLVX) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,724,000 shares of the company’s stock, valued at approximately $13,919,000. HilleVax makes up 52.4% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its largest holding. Takeda Pharmaceutical Co. Ltd. owned approximately 13.50% of HilleVax at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Braidwell LP bought a new stake in HilleVax in the third quarter worth about $1,873,000. JPMorgan Chase & Co. raised its holdings in shares of HilleVax by 1,376.8% in the 4th quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company’s stock worth $429,000 after purchasing an additional 193,124 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of HilleVax in the 3rd quarter worth approximately $331,000. Zacks Investment Management lifted its stake in HilleVax by 411.9% during the third quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock valued at $163,000 after purchasing an additional 74,673 shares during the last quarter. Finally, Jane Street Group LLC grew its position in HilleVax by 81.7% in the third quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after buying an additional 35,546 shares during the last quarter. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Trading Down 1.8 %

Shares of HLVX opened at $1.61 on Thursday. HilleVax, Inc. has a 1-year low of $1.55 and a 1-year high of $17.23. The business’s 50-day moving average price is $1.83 and its 200 day moving average price is $1.86. The stock has a market capitalization of $80.19 million, a P/E ratio of -0.52 and a beta of 0.76.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.